ASLAN Pharmaceuticals Completes Enrolment for Global Pivotal TreeTopp Study Ahead of Schedule
ASLAN Pharmaceuticals Limited - American Depositary Shares (ASLN)
US:NASDAQ Investor Relations:
ir.aslanpharma.com
Company Research
Source: GlobeNewswire
SINGAPORE, Jan. 02, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced the completion of patient enrolment in TreeTopp (TREatmEnT OPPortunity), a global pivotal study investigating varlitinib in second-line biliary tract cancer (BTC). Topline data is expected in the second half of 2019. TreeTopp is a randomised, double-blind, placebo-controlled clinical trial in second-line BTC comparing varlitinib and capecitabine to placebo and capecitabine. It is the largest global, placebo-controlled study in BTC conducted to date. Currently, there are no approved targeted therapies for the treatment of BTC which affects more than 200,000 people in Asia every year. The study recruited 127 patients who have failed first line therapy from 56 sites worldwide including the US, Europe, Australia, Japan, Kore
Show less
Read more
Impact Snapshot
Event Time:
ASLN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ASLN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ASLN alerts
High impacting ASLAN Pharmaceuticals Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ASLN
News
- Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders [Yahoo! Finance]Yahoo! Finance
- Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and DisordersGlobeNewswire
- ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $10.00 price target on the stock, down previously from $15.00.MarketBeat
- ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) had its price target lowered by analysts at HC Wainwright from $17.00 to $9.00. They now have a "buy" rating on the stock.MarketBeat
- ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering [Yahoo! Finance]Yahoo! Finance
ASLN
Sec Filings
- 3/28/24 - Form D
- 3/25/24 - Form F-3
- 3/21/24 - Form SC
- ASLN's page on the SEC website